服務熱線
021-60498804
| Cat. Number | A9714 |
| Chemical Name | A9714 AZD-1152-HQPA 722544-51-6 |
| CAS Number | 722544-51-6 |
| Mol. Formula | C26H30FN7O3 |
| Mol. Weight | 507.56 |
| Qty 1 |
1mg |
| Qty 2 | 10mg |
| Appearance | Off-white Powder |
| Application Notes | ≥98% |
| Synonym | AZD1152-HQPA |
| Solubility | DMSO 102 mg/mL (200.96 mM) Ethanol 3 mg/mL (5.91 mM) Water Insoluble |
| Storage condition | -20°C |
| References | AZD-1152-HQPA inhibits aurora kinases B and C (AurB, AurC), preventing mitotic spindle formation and proper completion of mitosis. This compound exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for cancers with solid tumors. In acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) cells, AZD-1152-HQPA induces apoptosis, inhibiting proliferation. AZD-1152-HQPA also induces apoptosis in glioma cells, inhibiting proliferation in vitro and tumor growth in vivo. ReferencesHartsink-Segers SA, Zwaan CM, Exalto C, et al. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target. Leukemia. 2013 Mar;27(3):560-8. PMID: 22940834. Diaz RJ, Golbourn B, Shekarforoush M, et al. Aurora kinase B/C inhibition impairs malignant glioma growth in vivo. J Neurooncol. 2012 Jul;108(3):349-60. PMID: 22382783. Boss DS, Witteveen PO, van der Sar J,et al. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol. 2011 Feb;22(2):431-7. PMID: 20924078. |
下一個：CYC-116上一個：VORINOSTAT |
|
Copyright ? 2022 上?；菡\生物科技有限公司
滬ICP備2021037845號-6
